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Uveal melanoma (UM) is the most common primary intraocular malignancy affecting adults. Despite successful local treatment of
the primary tumour, metastatic disease develops in up to 50% of patients. Metastatic UM carries a particularly poor prognosis, with
no effective therapeutic option available to date. Genetic studies of UM have demonstrated that cytogenetic features, including
gene expression, somatic copy number alterations and speciﬁc gene mutations can allow more accurate assessment of metastatic
risk. Pre-emptive therapies to avert metastasis are being tested in clinical trials in patients with high-risk UM. However, current
prognostic methods require an intraocular tumour biopsy, which is a highly invasive procedure carrying a risk of vision-threatening
complications and is limited by sampling variability. Recently, a new diagnostic concept known as “liquid biopsy” has emerged,
heralding a substantial potential for minimally invasive genetic characterisation of tumours. Here, we examine the current evidence
supporting the potential of blood circulating tumour cells (CTCs), circulating tumour DNA (ctDNA), microRNA (miRNA) and
exosomes as biomarkers for UM. In particular, we discuss the potential of these biomarkers to aid clinical decision making
throughout the management of UM patients.
British Journal of Cancer; https://doi.org/10.1038/s41416-022-01723-8

INTRODUCTION AND BACKGROUND
Uveal melanoma (UM) is the most common, and deadliest, form of
primary intraocular malignancy affecting adults. Uveal melanomas
can arise in any part of the uveal tract, including the iris, ciliary
body, and choroid (Fig. 1), but most UM develops in the choroid
(~90%) [1]. Initial detection of UM commonly occurs through
regular visits to optometrists or ophthalmologists, based on
clinical features and irrespective of the presence of typical
symptoms such as increased ﬂoaters, blurred vision, ﬂashes, or
loss of peripheral vision, during routine clinical examinations [2].
Formal diagnosis of UM, however, occurs through clinical
examination by an ophthalmologist with experience in ocular
tumours (ocular oncologist). Features such as subretinal ﬂuid,
orange pigment and documented growth, combined with
imaging techniques such as ﬂuorescein angiography and ocular
echography are needed to accurately diagnose patients [3].
Early diagnosis is crucial in the treatment and outcome of UM.
For example, patients with delayed diagnosis due to misdiagnosis
as a naevus or macular degeneration, or failure to detect the
tumour during ophthalmoscopy, are more likely to be treated with
enucleation rather than more conservative options, such as local
resection or plaque radiotherapy [4]. Furthermore, allowing the
tumour to grow, even by as little as one millimetre, has been
shown to increase the risk of developing metastases by 6–51%,
based on its current size [5]. Thus, early detection and treatment
interventions are critical for optimal management and improved
outcome of this disease.

Here, we summarise the current literature on the clinical
management of UM based on histological and genetic features.
We discuss the current limitations and highlight how blood-based
liquid biopsies could be used in the diagnosis, prognostication,
and earlier treatment of UM.
CURRENT TREATMENT PARADIGM
Management of UM varies depending on tumour location and
size, visual acuity on presentation, local medical expertise and
infrastructure available for treatment modalities like proton
beam irradiation, and, ultimately, on patient wishes [6]. Iris
melanoma is usually treated with radiation, preferably proton
beam irradiation, followed by brachytherapy. Although less
common, surgical resection is also used [1]. In contrast,
treatment for ciliary body and choroidal melanoma varies
signiﬁcantly depending on several ocular and patient factors.
Most patients with posterior UM are currently treated with
plaque radiation therapy, stereotactic radiosurgery or enucleation. Other available treatment options include proton beam
radiotherapy, transpupillary thermotherapy, laser photocoagulation, and rarely, local surgical resection [7, 8]. Overall, the
tendency is to treat large, rapidly growing lesions more urgently
and aggressively. However, based on evidence suggesting that
small primary UM tumours are capable of rapid growth and
metastatic spread [5], there is a trend away from observation of
small tumours, favouring earlier intervention [9].
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Uveal Melanoma Locations. Macroscopic images of uveal melanoma in the choroid (a), ciliary body (b), and iris (c).

Local treatment of the primary UM has improved dramatically in
the last 30 years, with increased use of conservative treatments
and therapies aimed at preserving the eye [8]. However, survival
rates of patients who develop metastatic disease remains dismal,
with the 5 year survival rate, from 1973 to 2008, remaining under
10% [10]. This is similar to a recent update reported by Aronow
et al. [11] where the 5-year relative survival rate was 80.9% from
1973 to 2013; and our recent report showing no signiﬁcant
change on the 5-year survival rate from 1982 to 2011 in Australia
with an average of 81% [12]. This underscores that improvements
in the management and control of that the localised disease have
had little to no impact on the development of incurable
metastases.
Following a diagnosis of UM, patients are screened for
metastatic disease, usually with imaging of the liver by
ultrasound, magnetic resonance imaging (MRI) and other liver
function tests. Positron emission tomography-computed tomography (PET-CT) is also used in some practices [13]. At the time
of diagnosis, less than 4% of UM patients have radiologically
detectable metastatic disease [14]. However, approximately
50% of patients develop metastatic disease after 2.4–4.4 years
[15–18] following diagnosis of the primary tumour. Haematogenous dissemination of UM cells commonly leads metastases
towards the liver (93%), followed by lung (24%) and bones
(16%) [19] and only rarely to the brain, skin, or other body sites.
Metastatic UM is fatal in most cases, with death occurring in
80% of patients within 1 year, and 92% within 2 years of
diagnosis of metastases [20]. Therefore, following local treatment of the primary tumour, metastatic screening is generally
recommended but is performed at the discretion of the treating
ophthalmologist or oncologist, taking into consideration the
results of prognostic testing performed and the wishes of the
patient.
Demographic, clinical, and histological features of the primary
UM have been found to correlate with patient outcome
after adjustment for baseline death rates in the general
populations [16]. Poor prognostic features include older age at
presentation, being male, larger tumour basal diameter
and thickness, ciliary body location, diffuse tumour conﬁguration, association with ocular/oculodermal melanocytosis, extraocular tumour extension, and more advanced tumour staging
using the American Joint Committee on Cancer classiﬁcation
(AJCC) [21]. In addition, certain histopathological features
of the tumour also carry prognostic value, including evidence
of epithelioid cell types, high mitotic activity, increased
human leucocyte antigen (HLA) expression, tumour inﬁltration
by proangiogenic M2-macrophages (TAMs) and lymphocytes
(TILs), higher expression of insulin-like growth factor-1
receptor (IGF1R), microvascular loops and networks, and
extracellular matrix patterns [22]. While classically clinical and
histopathological features were used to predict patient prognosis, genetics has more recently come to the forefront of UM
prognostication.

GENETIC PROGNOSTIC BIOMARKERS: CHROMOSOMAL
ABNORMALITIES, GENE EXPRESSION PROFILING AND DRIVER
MUTATIONS
Accurate characterisation of the metastatic risk of individual
patients is now possible through genetic proﬁling of UM tumours,
which allows identiﬁcation of changes relevant for prognosis such
as somatic copy number alterations (SCNAs), gene expression
proﬁling, or speciﬁc gene mutations [23].
Gene expression proﬁles
Studies have revealed that mRNA-based gene expression proﬁling
can differentiate two distinct molecular forms of UM cells. Class 1
UMs have a low risk of metastasis, with gene expression similar to
normal uveal melanocytes, whilst class 2 UMs harbour high-risk of
metastases, with a more primitive stem-like gene expression
proﬁle [24]. As a result, a test utilising 15 differentially expressed
mRNA, including 12 class discriminating genes, was developed
and is commonly used clinically in North America under the name
DecisionDx-UM [25]. While the genes selected for the test are
associated with loss of chromosome 3 and gain of chromosome
8q, the overall gene expression differences observed between
class 1 and 2 are only partially explained by chromosomal
alterations [26]. The gene expression proﬁling test, DecisionDxUM, has been prospectively validated by two independent
multicentre studies, stratifying patients into low-risk class 1 or
high-risk class 2 groups. Onken et al. showed from 446 cases
analysed, metastases were detected in 3 class 1 cases (1.1%) and
44 class 2 cases (25.9%), over a median of 17.4 months of follow
up [27]. Plasseraud et al., showed that class 1 patients had a 100%
3-year metastasis-free survival, whereas class 2 patients had a 63%
3-year metastasis-free survival, with a median time to metastases
of 1.4 years [25]. More recently, it was shown that the expression
of the preferentially expressed antigen in melanoma (PRAME)
gene can aid the identiﬁcation of a proportion of class 1 tumours
that give rise to metastatic disease (class 1b) [28]. PRAME is a
protein that functions as an inhibitor of retinoic acid signalling,
which prevents cell proliferation, differentiation, and apoptosis
[29]. Inclusion of PRAME gene expression further improved the
prognostic predictive power of the DecisionDx-UM test [28]. Thus
it should be noted that the study by Plasseraud et al. did not
incorporate PRAME expression into their classiﬁcation, with two
class 1 patients developing metastases at 3.24 and 4.37 years
following diagnosis [25].
Somatic alterations: copy number variations and somatic
mutations
As early as 1990, chromosomal abnormalities were noted in UM cells
[30], with loss of one copy of chromosome 3 (monosomy 3) found in
approximately 50% of tumours [31]. Monosomy 3 has been reported
in 67-84% of metastatic UM [32, 33] and approximately 21% in nonmetastasising UM [32]. Furthermore, gain of chromosome 8 affects
approximately 40% of UM, and commonly co-occurs with loss of
chromosome 3 and metastasis [34], which may or may not co-occur
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with the loss of 8p, loss of 6q and loss of 1p [35]. In particular, the
combination of monosomy 3 and gain of 8q has been shown to
confer an extremely poor prognosis [23, 36]. Conversely, other
chromosomal alterations are associated with an improved prognosis, including gain of chromosome 6p [37], which is virtually
mutually exclusive with loss of chromosome 3 [38]. Based on these
SCNAs, a commercially available multiplex ligation probe ampliﬁcation (MLPA) kit to detect changes to chromosome 1p, 3, 6, and 8 was
developed and validated to predict patient prognosis [39]. More
recently, a study including 658 primary UM patients, the largest
retrospective cohort to date, further demonstrated that SCNA-based
classiﬁcation predicts the risk of melanoma-related metastasis [36],
and is more accurate at predicting metastases than AJCC staging
[40]. New algorithms such as the Liverpool Uveal Melanoma
Prognosticator Online (LUMPO) [41] and Prediction of Risk of
Metastasis in Uveal Melanoma (PRiMeUM) [42] combine clinical,
histological, and somatic copy number alterations to further reﬁne
patient prognostication.
Furthermore, it is known that certain somatic mutations are
highly recurrent in UM independently of prognosis, while others
co-occur with speciﬁc SCNAs and prognostic classes [23].
Somatic mutations to the G Protein Subunit α11 (GNA11) and G
Protein Subunit αq (GNAQ) in codons Q209 and R183 have been
known to occur in >90% of UMs [23, 43]. In addition, mutations
to the phospholipase C beta 4 (PLCβ4) in the codon D630 [44];
and cysteinyl leukotriene receptor 2 (CYSLTR2) in the codon L129
[45] were found in GNAQ/GNA11 wild-type UMs. The above
mutations are largely mutually exclusive and found within the
same cellular pathway [45]. Therefore, they are thought to
constitute the means for UM cells to achieve constitutive
activation of the mitogen activated protein kinase pathway
(MAPK) and the phosphatidylinositol-4,5-bisphosphate 3-kinase
(PI3K)/protein kinase B (AKT) pathway.
Although mutations to GNA11, GNAQ, PLCβ4, and CYSLTR2 do
not correlate with prognosis, somatic mutations to the deubiquitinating enzyme BRCA1 associated protein 1 (BAP1), splicing
factor 3B subunit 1 (SF3B1), and eukaryotic translation initiation
factor 1A X-linked (EIF1AX) are associated with prognosis.
Inactivating somatic mutations to BAP1 are found in 44–66%
primary UM [23, 43] and in around 84% of UM metastases, and are
associated with poor prognosis [23, 46]. Inactivation of BAP1 has
been shown to induce a metastatic phenotype in vitro and is
associated with low oxidative phosphorylation and reliance on
fatty acid oxidation [47]. Furthermore, the location of BAP1 on
chromosome 3p may explain the association between loss of
chromosome 3 and inactivation of BAP1 on the remaining
chromosome 3. In contrast, mutations to SF3B1 have been shown
to correlate with intermediate prognosis and disomy of chromosome 3. Similarly, mutations to EIF1AX are also associated with
disomy of chromosome 3 and shown to be correlated with a good
prognosis [48].
A comprehensive integrative analysis by The Cancer Genome
Atlas Program revealed a strong association of somatic alterations
and gene expression proﬁles, which deﬁne four molecularly distinct
clinically relevant subtypes of UM. These SCNA clusters were further
validated by Vichitvejpaisal et al. in 2019 in 658 eyes at the Wills Eye
Hospital. This study referred to these as clusters A–D rather than
1–4 as used in the TCGA study [36]. Cluster 1 tumours are
characterised by EIF1AX mutations, gain of chromosome 6p or
neutral SCNA proﬁles; and are associated with good prognosis, with
only 4% of patients developing metastases after 5 years from
diagnosis [36]. Cluster 2 tumours carry SF3B1 mutations and gain of
chromosome 6p, loss of chromosome 6q and gain of chromosome
8q, and are associated with a 5-year metastatic risk of 20%. Lastly,
cluster 3 and 4 tumours are associated with poor prognosis and
carry BAP1 mutations and loss of chromosome 1p, loss of
chromosome 3, loss of chromosome 6q, loss of chromosome 8p
and gain of chromosome 8q. (Fig. 2) [23, 36]. The risk of developing
British Journal of Cancer
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Fig. 2 Genetic pathways of uveal melanoma progression. Nonprognostic mutations to GNA11, GNAQ, PLCβ4, and CYSLTR2 may
drive the transformation from normal uveal melanocyte to early UM.
Further genetic abnormalities dichotomise uveal melanoma into
several prognostic groups. Patients with mutations to EIF1AX
generally have the best prognosis and have no SCNA or G6p.
Patients with mutations to SF3B1 have an intermediate prognosis
and have G6p and/or abnormalities to chromosome 8. Lastly,
patients with mutations to BAP1 have loss of chromosome 3 and
gain of 8q, with larger gains in 8q equating to a shorter time to
metastases. Each class of tumour may release CTCs at different rates
and quantities, and may cause the formation of metastases.

metastases by 5 years, increased from 33% to 63% depending on
the level of 8q gains, and therefore, further subdivided as cluster 3
and cluster 4, respectively [36].
As a result of the overwhelming evidence, the new guidelines
set out by the National Comprehensive Cancer Network (NCCN)
incorporated the aforementioned clinical, histopathological and
genetic features to provide clinicians with an up to date treatment
and care guidelines [6]. Patient prognostication by gene expression proﬁling and/or SCNA, is critical to inform systemic imaging
frequency based on the highest risk factor present. Surveillance
imaging frequency varies from yearly to three-monthly radiological scans, for low and high-risk groups, respectively. As no
systemic therapies that can improve overall survival are currently
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available, once metastases are detected, the primary directive is to
enrol patients into clinical trials or liver-directed therapies.
TUMOUR SAMPLING AND IMPLICATIONS OF PROGNOSTIC
TESTING
Fine-needle aspiration biopsy (FNAB), usually performed at the
time of plaque brachytherapy, is the most frequently used
technique for biopsy of UM for molecular analysis. However,
incisional biopsy, with or without vitrectomy surgery, is also
performed routinely in some centres. The biopsy technique
chosen depends upon the size, conﬁguration, and most importantly the location of the tumour. For iris tumours, entry into the
anterior chamber can be accomplished using a 26- to 30-gauge
needle under direct visualisation with an operating microscope
[49]. The needle is inserted bevel up and is swept gently over the
surface of the tumour, while approximately 0.5 mL of aqueous
ﬂuid containing the specimen cells is aspirated. Posterior-segment
tumours can be biopsied via a transscleral or a transvitreal
approach. The transscleral approach, in which the biopsy needle is
passed through the sclera and into the tumour, is the most
commonly employed, and is suitable for biopsy of UM located
within the ciliary body or the anterior choroid [50]. Alternatively,
an incisional approach can be used, in which a partial thickness
scleral ﬂap is fashioned, and the choroid exposed by a fullthickness scleral incision, allowing biopsy forceps to capture a
much larger specimen than can be obtained using FNAB
techniques. Tumours located posterior to the equator can be
approached via a transretinal technique through the vitreous
cavity, either by FNAB via the pars plana, or via vitrectomy surgery.
Excisional biopsy, using the technique of lamellar sclerouvectomy, is performed infrequently, since most UM are
unsuitable due to size, conﬁguration or location. This technique
can achieve complete local tumour control and excellent
visual outcomes. However, the surgery is technically challenging, requires prolonged hypotensive anaesthesia, and carries a
signiﬁcant risk of complications including vitreous haemorrhage
[51], rhegmatogenous retinal detachment, and local recurrence
(25–35%, 10 years) [52].
Whilst FNAB can provide useful diagnostic and prognostic
information, all biopsy techniques carry the risk of complications,
including haemorrhage and infection, which may be sightthreatening. Furthermore, insufﬁcient material for diagnostic
purposes has been reported in ~8–20% of FNAB cases [50, 53]. A
large prospective interventional case series (n = 150) indicated
that transvitreal or transcorneal routes have higher rates of
failure compared to the transscleral route, presumably due to
lower tissue yield. Moreover, negative results were signiﬁcantly
correlated with small tumour sizes (basal diameter <5.0 mm;
apical height <2.5 mm) [50]. This likely reﬂects the clinical
difﬁculty of obtaining sufﬁcient biopsy material from smaller
tumours. Current evidence suggests that early treatment of UM
leads to improved patient survival [5]. However, prognostic
testing may be more difﬁcult to perform in these smaller
tumours due to lower specimen yield. Additional factors that
may reduce accurate prognostication include tumour heterogeneity and sampling errors [54].
Local seeding of tumour cells along the biopsy track has been
raised as a possible risk of UM biopsy, and appears to be rare,
however local recurrence of melanoma following FNAB has been
reported [55]. In a study of 170 FNABs, there were no reported
cases of local treatment failure, endophthalmitis or orbital
dissemination. Metastatic disease developed in 14 patients and
retinal detachment occurred in 3 cases, but none of these were
directly associated with FNAB [56].
There is a demonstrable need for alternative methods of
prognostic testing for patients with UM. Recently, we described
accurate identiﬁcation of SCNAs in primary FFPE UM tumour

samples using whole genome ampliﬁcation and low-pass whole
genome sequencing [57]. This method could support current
clinical practice to help overcome failure rates due to sub-optimal
tissue yields from FNAB.
Prognostic testing of UM carries psychological consequences
for patients. With rare exceptions, systemic therapy does not
reduce mortality or prolong survival in patients with metastatic
UM. Nevertheless, studies have shown that the majority of
patients wish to know prognostic information about risk of
metastasis, even though no accepted and effective treatments
exist for disseminated disease. The most important reason for UM
prognostication is to provide patients with information that would
be helpful in making life-changing decisions [58]. A recent study
evaluating the psychological needs of patients discovered that of
261 UM patients, 79.5% needed psychological intervention [59].
BLOOD BIOMARKERS
A growing number of publications, including our own, have
documented that tumour derived material can be detected in the
circulating blood, serving as “liquid biopsies” (Fig. 3a). Liquid
biopsies provide a minimally invasive alternative for diagnosis,
prognosis, and monitoring of cancer. In particular, circulating
biomarkers such as circulating tumour cells (CTCs), circulating
tumour DNA (ctDNA), and Circulating Micro RNA (cmiRNA) have
been explored for the management of UM through the
application of new technologies (Fig. 3b, c) in combination with
clinical studies.
Circulating tumour cell enumeration
CTCs are tumour cells that have disseminated into the vascular or
lymphatic system of cancer patients, believed to facilitate the
formation of metastases. Histopathological analysis of 643 eyes
enucleated from patients with UM demonstrated that intravascular ingrowth of tumours occurred frequently with other wellstudied histopathological features of poor prognosis (epithelioid
cell type, intrascleral growth and large tumour size) [60]. It is
generally accepted that the eye has no well-developed lymphatic
drainage [61]. This may suggest that a haematogenous route of
dissemination through the release of CTCs might be common in
UM and may be a critical step in the process of metastasis.
Studies across multiple malignancies have demonstrated that
CTCs may be used to predict prognosis, response to therapy and
disease recurrence [62]. For example, in castrate-resistant prostate
cancer patients highlighted the clinical utility of AR-V7 variant
identiﬁcation on CTCs to inform and improve treatment outcomes,
relative to decisions based on current standard of care [63]. A
recent meta‐analysis of 21 studies showed that CTC enumeration
as a prognostic marker in non-metastatic breast cancer patients
[64]. Moreover, detection of CTCs before neoadjuvant chemotherapy was signiﬁcantly associated with reduced overall, distant
disease-free and locoregional relapse-free survival [64]. In addition, a pooled analysis of 18 cohorts supported the use of CTC
enumeration for staging of metastatic breast cancer [65].
A recent large study in cutaneous melanoma revealed that
detection of ≥1 CTC in stage III patients was a signiﬁcant predictor
of decreased 6-month and 54-month relapse-free survival [66].
Such a test could be used to identify patients who may beneﬁt
from adjuvant therapies. Moreover, we have demonstrated the
heterogeneous nature of cutaneous melanoma CTCs [67], that CTC
subpopulations respond dynamically to therapy [68] and that the
presence of speciﬁc CTC phenotypes is predictive of response and
progression-free survival [68]. All the above underscores the
potential of CTCs as a cancer biomarker.
Detection of CTCs in UM was originally accomplished using
cytochemistry and standard microscopy techniques [69, 70].
Initially, the wide-spread use of reverse transcriptase-polymerase
chain reaction (RT-PCR) was used to detect UM speciﬁc mRNA
British Journal of Cancer
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Fig. 3 Liquid biopsy. a CTCs, ctDNA, and cmiRNA are minor components of the blood, mixed with the normal erythrocytes, leucocytes, and
cell-free nucleic acids. A minimally invasive venous blood collection has the potential to provide genetic information of all tumours within the
body. b Plasma derived circulating nucleic acids (DNA, RNA, miRNA) are generally extracted using commercially available kits. Following
extraction, ctDNA or cmiRNA can be detected by real time-qPCR, digital PCR or NGS, to detect the presence of disease, to detect mutations or
SCNAs for diagnostic, prognostic, or genetic changes in response to therapy. c Circulating tumour cells are isolated from the blood by
antibody directed methods such as immunomagnetic beads, or through their physical properties such as size and deformability. Once
isolated, CTCs can be indirectly quantiﬁed using RT-PCR, or directly quantiﬁed using immunocytochemistry. Fluorescence in-situ hybridisation
(FISH) can be used to detect SCNAs or changes to mRNA or miRNA expression. Single cell sequencing of CTCs can provide mutational and/or
chromosomal copy number information.

transcripts. These studies targeted tyrosinase, melanoma antigen
recognised by T-cells 1 (MART1) and glycoprotein 100 (gp100), and
more recently, markers of epithelial to mesenchymal transition
(Supplementary Table 1) [71–81]. In general, RT-PCR based gene
expression has been associated with worse outcomes in primary
UM [71, 73–75, 77, 78], but the number of patients with detectable
CTCs has been low with a couple of studies not detecting CTCs in
primary UM [72, 81]. Lastly, there are limited studies assessing
metastatic UM CTCs, but generally CTCs are readily detectable
[71, 74, 79], and their presence has been shown to be associated
with shorter PFS and OS [79].
Although RT-PCR is a relatively straightforward technique to
indirectly infer the existence of CTCs, it does not provide
conclusive evidence of the presence of CTCs. Furthermore, RTPCRs do not provide phenotypic or genotypic information of the
CTCs, nor can it differentiate between CTCs and circulating RNA.
As an alternative, direct capture and enumeration of CTCs have
been evaluated as prognostic biomarkers in UM patients.
Immunomagnetic isolation, using covalently conjugated antibodies directed against common UM surface antigens bound to
ferric ﬂuids or beads, is the most common method utilised today
for CTC enrichment. Reports on the direct quantiﬁcation and
characterisation of CTCs by immunomagnetic capture and sizebased isolation are listed in Table 1.
Commonly, the melanoma associated chondroitin sulphate
proteoglycan (MCSP, also known as chondroitin sulphate proteoglycan 4—CSPG4, high molecular weight-melanoma associated
antigen—HMW-MAA or neural glial antigen 2—NG2) has been
used as target for capture of UM CTCs. Using this approach, CTCs
were detected from 40 to 50 mL of peripheral blood in 1.6–19% of
patients with primary UM [82–84], and their detection in one study
correlated with known clinical features of poor prognosis [84]. In a
follow up study from Ulmer et al. 2008, Suesskind et al. 2011 used
immunomagnetic isolation of with MCSP alone but not ﬁnd any
correlation between the quantity of CTCs and the metastatic
propensity of the tumour over a median follow up time of
16 months [83]. In our recent study, we used MCSP to isolate CTCs
British Journal of Cancer

in 69% of primary UM patients prior to treatment from only 8 mL
of blood. We found that the presence of CTCs was not associated
with tumour size or prognostic class [85]. Similar ﬁndings have
been reported by Tura et al. [86], potentially indicating that the
haematogenous dissemination of tumour cells is not a determinant of metastasis in UM. Rather, cellular programs that underpin
the molecular classes drive metastases by enhancing metastatic
colonisation, primarily to the liver. In addition to MCSP,
immunomagnetic isolation using melanoma cell adhesion molecule (MCAM) has been utilised in the isolation of CTCs in UM
patients using the CellSearch system [87–90]. In primary cases,
capture rate has ranged from 30 to 50% [87, 88] with some
evidence that enumeration of CTCs in early stage UM predict
increased metastatic risk and increased mortality [87]. The above
results suggest that targeting only one surface antigen is not
enough to capture CTCs in most UM patients. To overcome this
limitation, CD63 and gp100 were used in combination for
immunomagnetic enrichment, and CTCs were detected in 94%
of 31 UM patients from 50 mL of peripheral blood [86].
Furthermore, we have also utilised a multimarker CTC isolation
approach, targeting ABCB5, gp100, MCAM, and MCSP and found
that CTCs were detectable in 86% of 43 primary UM patients from
8 mL of blood correlating with shorter PFS and OS [91]. Indeed it
appears as though currently the combination of CD63 and gp100
or for the isolation of CTCs in primary UM is the most suitable
capture technique, given that all studies from this group have
achieved >90% detection rate [86, 92–94] with median cell counts
>1.66 per 10 mL of blood. Lastly, in addition to RT-PCR and
immunomagnetic isolation, primary UM CTCs have been isolated
using ﬁltration with a detection rate of 31–54% patients with
localised disease [78, 95]. Using the ISET ﬁltration system, it was
shown that more than 10 CTCs per 10 mL of blood were an
indicator of poorer prognosis over a 24 month period [95].
Even though most CTC isolation studies have focused on
primary disease, some studies also have investigated metastatic
UM. Initially, Bidard et al. 2014 described the use of the CellSearch
system to detect CTCs in metastatic UM where CTCs were
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P

P

P

P

P
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Ulmer
[84]

Eide
[82]

Pinzani
[78]

Suesskind [83]

Tura
[86]

Mazzini
[95]

Bidard
[89]

Bande
[88]

Terai
[90]

NS

P

Ulmer
[100]

Tura
[93]
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IMC

IMC-CS

IMC-CS

IMC-CS

ISET

IMC

IMC

ISET

IMC

IMC

IMC
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Direct CTC detection studies in UM.
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CD63, gp100/
CD63, MCSP

MCAM/MCSP

MCAM/MCSP

MCAM/MCSP

NA/H&E

CD63, gp100/
MCSP, CD63

MCSP/MCSP

NA/H&E

MCSP, CD276/ LM

MCSP/MCSP

MCSP/MSCP

Capture/
Detection Marker

Li-Ha

CS

CS

CS

EDTA

Li-H

H

ISET:
EDTA

H

H

H

Blood Tube

50a

7.5

7.5

7.5

10

50

50

ISET:
10

40

50

50

Blood
Vol (mL)

BL:
13/94 pUM
FU:
9/94 pUM
29/31 pUM
17/31 pUM

12/40 mUM

4/8 pUM

AB:
17/17 pUM
VB:
9/17 pUM

Ib

≤3
≤3

≤72

≤72

≤72

40/44 pUM

ISET:
5/16 pUM

≤4

≤3a

4/249 pUM

10/52 pUM

Ib

NS

NA

Detection Rate

I

TTP (hrs)

2.4/10 mL
(0–10.2)

AB: 5
(1–168)
VB: 1 (2–17)

0.5 (1–3)

(1–20)

8 (2–50)

3.5/10 mL
(0–10.2)

BL:
1 (1–8)
FU:
7.5(1–26)

2 (0.75–5.8)

NS

2.5 (1–5)

NA

# CTCs

58% of 44 cases were positive
for monosomy 3.
11 patients were tested for
monosomy 3 in CTCs compared
to tissue using immune-FISH. 10/
11 CTC monosomy matched the
tumour. Monosomy 3 in CTCs

Arterial blood was far superior to
venous blood for detection of
CTCs. Patients with both hepatic
and extra-hepatic metastases
showed signiﬁcantly more CTCs
in arterial blood compared to
liver alone.

No correlation between CTC
positivity and LBD & apical
height.

CTC count was strongly
associated with the presence of
miliary hepatic metastases,
metastases volume, ctDNA level,
PFS, and OS.

CTC clusters are detectable
through ISET. > 10 CTCs was
indicative of larger LBD, apical
height, and disease-free survival.

CTCs were also identiﬁed after
short-term culture.

No signiﬁcant difference in CTC
numbers between pre- and
-post treatment of the primary
tumour. No association between
CTCs and prognostic features.

ISET CTCs correlated with
tyrosinase levels, and where
tyrosinase was negative, ISET
CTCs were negative.

CTCs were detected in bone
marrow. 98/328 positive with a
median of 56 and a range of
1–500 cells detected.

CTC detection was associated
with ciliary body involvement,
advanced tumour stage, and
anterior anatomical location

aCGH conﬁrmed SCNAs in UM
CTCs. Cutaneous and uveal CTC
numbers were pooled together.

Summary of outcomes
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P

P

R

NS

P

Beasley
[85]

Anand
[87]

Maaßen
[92]

Tura
[94]

Beasley [91]

IMC

IMC

IMC

IMC-CS

IMC

Enrichment method

ABCB5, gp100,
MCAM, MCSP/
MART1,
gp100, S100β

CD63, gp100/
CD63, MCSP

CD63, gp100/
CD63, MCSP

MCAM/MCSP

MCSP/MART1,
gp100, S100β

Capture/
Detection Marker

50a

Li-Ha

8

50a

Li-Ha

EDTA or
TransFix

7.5

8

Blood
Vol (mL)

CS

EDTA

Blood Tube

BL:
6/20 pUM
8/19 mUM
FU:
8/19 pUM
13/19 mUM
19/20 pUM

30/33 pUM

≤72

≤3a

≤3a

37/43 pUM

18/26 pUM;
1/1 mUM

≤24 (held
at 4 °C)

EDTA
≤1
Transﬁx
1–72

Detection Rate

TTP (hrs)

3/8
mL (1–89)

8.2/50
mL (0–51)

9.3/50
mL (0–51)

BL:
pUM:
Mean
1.73 (1–3)
mUM:
Mean
9 (1–38)

pUM:
2/8
mL (1–37)

# CTCs

≥3 CTCs was associated with
shorter PFS and OS.

CTCs with monosomy 3 had
signiﬁcantly less Adiponectin in
their pUM compared to CTC-ve
or CTCs with a lower percentage
of monosomy 3.

Systemic metastases were
associated with the presence of
monosomy-3, measured by
immune-FISH, in the primary
tumour and CTCs as well as a
higher GLUT1 ratio.

Landmark OS rate at 24 months
was signiﬁcantly lower in CTC
positive pUM.

One mUM case was used to
show SCNAs in UM CTCs
matching the primary tumour. In
pUM, CTCs counts did not
correlate with tumour size or risk
indicators.

correlated with advanced
tumour stage and was detected
in all 4 patients who developed
metastases in the study period.

Summary of outcomes

TTP time to process, NA not applicable, P prospective, R retrospective, NS not speciﬁed, I immediately, IMC immunomagnetic capture, IMC-CS immunomagnetic capture-cell search, RT-PCR reverse transcriptasePCR, LM light microscopy, pUM primary uveal melanoma, mUM metastatic uveal melanoma, H heparinised, EDTA ethylenediaminetetraacetic acid, PG PAXgene, CS CellSave, ISET isolation by size of tumour cells, AB
arterial blood, VB venous blood. Unless otherwise speciﬁed, venous blood was used, H&;E ; haematoxylin &; eosin, BL baseline, FU follow-up, PFS progression-free survival, OS overall survival, CTC counts are
displayed as “median (range)” unless otherwise speciﬁed.
a
Assuming based on Tura et al. [86].
b
Inferred based on Ulmer et al. [100].
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detected in 30% patients and CTC count was strongly associated
with the presence of miliary hepatic metastases, the total volume
of disease, progression-free survival, and overall survival [89].
CellSearch was also used to compare CTC counts between arterial
and venous blood from metastatic UM patients. CTCs were
detectable in 100% of arterial blood compared to 53% in paired
venous blood, with higher median cell counts and absolute ranges
[90]. More recently, Anand et al. 2019 found CTCs in 42% of
metastatic patients compared to only 30% at the primary localised
stage [87].
Despite the variety of CTC detection methodologies, there is
conﬂicting evidence on whether the enumeration of CTCs is
prognostically relevant in metastatic UM [89]. The combined data
indicates that CTCs are present in the blood of UM patients with
primary disease. Given the opposing results of some studies,
further investigation is needed to understand if a subtype of CTCs,
isolated by some speciﬁc methods, is associated with high-risk UM
and, therefore, prognostically relevant. Interestingly, circulating
melanocytes or “CTCs” have not shown to be detectable in
patients with ocular naevi [88, 95], which may identify cases at risk
of malignant transformation. Thus, this may present an opportunity for minimally invasive diagnosis, but given the limited reports
further validation is required.
Many different factors may affect the recovery and detection of
CTCs (Table 1, Supplementary Table 1) outside of the speciﬁc
detection system. For example, the use of ﬁxative tubes such as
Streck or CellSave have a marked improvement on CTC recovery
when analysis is delayed [96], but in general EDTA is suitable if
processing occurs quickly after blood draw. In UM, studies that
have utilised the CellSearch have opted for the companion
CellSave tubes, whereas others have used EDTA or heparin. In vitro
analysis of spiked “CTC mimic” in EDTA tubes showed signiﬁcant
reduction of recovered cells after 1 h [97]. However, storage
temperature was not noted in this study which may also be a
crucial factor as it is in ctDNA. Other important factors include the
input sample type, such as from whole blood (ISET/CellSearch),
white blood cells after red blood cell lysis, or peripheral blood
mononuclear cells, which may all potentially confound isolation
and analysis due to different background levels and types of
leucocytes and this has been quite varied historically in UM.
Circulating tumour cells genetic analysis
Beyond enumeration, CTCs can be used as accessible samples to
analyse the genetic proﬁle of the tumours in an individual.
Previous work has indicated that CTCs can be used to detect
tumour-speciﬁc mutations and SCNAs. For example, in small-cell
lung cancer, SCNAs found in CTCs that could with reasonable
certainty predict whether a tumour would respond to chemotherapy [98]. Similarly, in a pan-cancer study incorporating colon, lung,
gastric, and prostate cancer, tumour-speciﬁc mutations could be
sporadically detected in CTCs as well as focal SCNAs in the MYC
and PTEN genes in all CTCs which were only detected in minor
fractions of tumour cells within the primary tumour, possibly
indicating selection for metastases [99].
An early report showed the analysis of SCNAs from single UM
CTCs using array comparative genomic hybridisation (aCGH). In
this study, the authors found that the aCGH proﬁles of the MCSP
positive UM CTCs had aberrations indicative of UM, such as
monosomy of chromosome 3. However, these cells were not
compared to the tumour of origin [100]. Another study utilised
ﬂuorescence in-situ hybridisation (FISH) targeting chromosome 3
and found that monosomy 3 could be detected in CTCs in 53% of
patients. Somatic copy number alterations to chromosome 3 in
CTCs and tumours were found to be highly concordant, with 91%
of the matched tumours and CTCs harbouring the same
chromosome 3 status [93]. Similarly, we showed that whole
genome ampliﬁcation (WGA) combined with low pass whole
genome sequencing (LP-WGS) can be used to proﬁle SCNA on UM

CTCs. The CTCs harboured proﬁles highly concordant with the
primary tissue [85]. Our results are supported by evidence that UM
genetic mutations and chromosomal aberrations found in the
primary tumour are also present in the patient-matched
metastases [101], as UM is regarded as genetically stable disease
[102]. The results of these studies support a model for detection of
SCNAs associated with UM prognosis through the analysis of CTCs.
However, this method needs rigorous clinical validation before it
can be used as an alternative prognostic test.
Circulating tumour DNA
Another blood based biomarker, increasingly attracting attention,
is circulating tumour DNA (ctDNA) (Fig. 3a–c) [103]. ctDNA forms
as a result of apoptosis or necrosis of tumour cells, or actively
secreted from tumour cells thus reﬂecting the evolving genetic
alterations of all solid tumours present at any one time within a
patient [104]. Clinically, ctDNA analysis can provide critical clinical
information. For example, in stage II colon cancer, previous
research has shown that ctDNA detection after resection provides
evidence that residual disease remains, that this identiﬁes patients
at a high-risk of relapse, and could be used to guide the use of
adjuvant chemotherapy [105]. Not only can the quantiﬁcation of
plasma ctDNA provide clinicians with treatment guidance, but also
the presence of druggable driver mutations in tumours. In nonsmall cell lung cancer, a common marker of resistance to EGFR
tyrosine kinase inhibitors is the EGFR T790M mutation. Detection
of this mutation in the plasma ctDNA by the FDA approved “cobas
EGFR Mutation Test v2” can be used to guide treatment selection,
allowing for treatment with Osimertinib [106]. More recently, the
approval of Guardant360 CDx by the FDA as the ﬁrst liquid biopsy
test that uses next-generation sequencing marks a new era for
mutation testing in oncology [107].
For cutaneous melanoma, ctDNA have been shown to correlate
with tumour size, accurately represent tumour mutations, detect
recurrence [108, 109] and treatment failure prior to radiological
imaging [110–112]. In addition, ctDNA detection can be used to
identify stage III melanoma patients at high-risk of relapse
[113, 114]. In UM, more than 95% of patients harbour mutually
exclusive recurrent mutations affecting GNA11 (Q209, R183), GNAQ
(Q209, R183), PLCβ4 (D630), or CYSLTR2 (L129) [23, 43]. Although
these mutations are not prognostic, they allow for the detection of
ctDNA in most patients, using a targeted approach. However,
there is limited literature on the use of ctDNA detection. Reports
on the detection and quantiﬁcation of ctDNA in UM patients are
listed in Table 2.
In primary UM, a recent study ctDNA was detected in 100% of
primary UM, and 50% of ocular naevi, with ctDNA levels
correlating with malignancy [115] using droplet digital PCR
(ddPCR) to detect mutation in GNAQ, GNA11, PLCβ4, and CYSLTR2.
In contrast, in our previous study ctDNA was only detectable in
26% of patients with primary UM prior to localised therapy [85]
using ddPCR, and did not correlate with clinical or histological
markers of disease. However, there was a slight trend toward
detection with increased tumour size. Other recent studies
conﬁrmed this ﬁnding, showing ctDNA detection in only 2% (3/
135) [116] using ultra-deep amplicon sequencing, or 9% (3/32)
using ddPCR [81] targeting known mutations in primary UM cases.
Thus, the detectability of ctDNA in primary UM is still controversial
and requires further investigation.
Currently, studies monitoring ctDNA in UM patients after
resolution of the primary lesion are conﬂicting. Some have shown
that ctDNA detection preceded the clinical diagnosis of metastasis
by 2–10 months [85, 116, 117]. In one of our case studies, ctDNA
detected metastases in a patient with low-grade lymphoproliferative disease and pulmonary embolism, which caused interference
of UM detection through PET-CT [85]. Conversely, one study
utilising Guardant360 CDx showed ctDNA was less sensitive than
MRI [118] at detecting metastatic disease. However, extensive
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300/20 → 1600/
10

820/10 →
16,000/10

≤24 (held
at 4 °C)

≤3

820/10 →
16,000/10

≤3

820/10 →
16,000/10

820/10 →
16,000/10a

≤3a

≤1

1500/10

≤0.5

NS

820/10 →
16,000/10

≤3

NS

Centrifugation
(xg/mins)

TTP (hrs)

Q + 1 µg
carrier RNA

Q

Q

NS

Q

Q + 1 µg carrier
RNAa

Q

Q + 1 µg
carrier RNA

Extraction Kit

NS

1-3
mL: 30
4-5
mL: 40

36

NS

36

NS

40

NS

Elution
Vol (µL)

1/1 mUM

8/30 pUM
8/8 mUM

BL:
2/3 mUM
FU:
2/3 mUM

0/32 high risk
surveillance
1/10 newly
developed muM
18/24 muM

18/22 mUM

51/54 mUM

9/28 mUM

20/21 mUM

Detection rate

NS

pUM:
0 (0–29)
mUM
178 (2–15,160)

BL:
0.5 (0–607)
FU:
3.7 (0–457)

Not stated

10 (2–9423)

30 (1–11,421)

0.03–38.4% FA

(1.3–2125)

ctDNA

Case study. ctDNA
was able to track the
response of a patient
with MBD4 mutation
to anti-PD1 therapy.
ctDNA levels changed
with response to
therapy.

ctDNA signiﬁcantly
higher in mUM
compared to pUM.
ctDNA detection in
pUM correlated with
tumour size. ctDNA in
a one patient case
study was detectable
prior to detection of
metastases by PET-CT.

Included NSCLC, UM,
and MSI-instable
colorectal cancer.

Abstract. MRI was
found to be more
sensitive than ctDNA
for detection of
metastases. Only
lesions >2 cm could
be detected.

ctDNA level
correlated with
hepatic miliary
metastases, CTC
positivity, and tumour
volume.
ctDNA levels were an
independent
prognostic factor for
PFS and OS.

Abstract. Correlated
with mUM tumour
burden.

ctDNA detection
correlated with bone
metastases. ctDNA
detection correlated
with younger age of
patients and larger
metastases.

ctDNA correlated with
tumour burden. The
only undetectable
sample had a tumour
volume of 0.43 cm3.

Summary of
outcomes
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ddPCR or NGS
(with UMI)

ddPCR

NGS (no UMI)

NGS

Park
[125]

Bustamante
[115]

Le Guin
[116]

Francis [117]

NS

EDTA

PG or SST

EDTA

EDTA

Blood Tube

2000/20 →
2000/20

1500/10b

≤1

≤0.5

2

1–5b

NS

NS

800/15 →
1600/10

≤4

1–4

NS

1500/10 →
3000/10

≤4

3

Centrifugation
(xg/mins)

TTP (hrs)

Volume (mL)

NS

Qb

Q

Q

Q

Extraction Kit

NS

40b

25

25

70

Elution
Vol (µL)

1/1 mUM

3/135 pUM
17/21 mUM or
recurrence

14/14 pUM
8/16 naevi

16/17 mUM

pUM
3/32
mUM
6/11

Detection rate

ctDNA was commonly
detected in mUM
compared to pUM.
The presence of
ctDNA was associated
with metastases with
80% sensitivity and
96% speciﬁcity.
Case study. Utilises
MSK-ACCESS. A
patient was
monitored every
6 months using MRI.
The patient had
ctDNA assessed
3 months after an MRI
and found ctDNA
which triggered
earlier reimaging
revealing metastatic
disease.

EIF1AX –
1.14% FA
GNAQ –
1.49% FA

ctDNA levels
correlated with
malignancy. In naevi,
ctDNA levels
correlated with
clinical risk factors.

Baseline ctDNA
correlated with LDH
and tumour size.
Lower median
baseline ctDNA levels
correlated with the
clinical beneﬁt group.
ctDNA predicted
response to targeted
therapy and
increasing ctDNA
preceded radiological
progression with
4–10-week lead time.

mUM had
signiﬁcantly more
ctDNA than pUM.

Summary of
outcomes

0.1–10% FA

pUM
3.75 (0.7–31.4)
Naevi
2.3 (1–13.3)

157.7 (Range
0–7172)

pUM
0 (0–0.13)
mUM
0.3 (0–108)
copies/µL

ctDNA

ctDNA levels at baseline, unless otherwise speciﬁed. All studies were prospective. ctDNA levels displayed as “median (range)” in copies/mL unless otherwise speciﬁed.
TTP time to process, Q QIAmp circulating nucleic acid, EDTA ethylenediaminetetraacetic acid, PG PAXgene, FA fractional abundance, UMI unique molecular identiﬁer, NS not speciﬁed, pUM primary uveal
melanoma, mUM metastatic uveal melanoma, bi-PAP bidirectional pyrophosphorolysis-activated polymerisation, NGS next-generation sequencing, ddPCR droplet digital PCR, PFS progression-free survival, OS
overall survival.
a
Assumed from Madic et al. [122].
b
Assumed from Metz et al. [121].
c
Based on Guardant360 CDx guidelines.
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prospective studies with standardised radiological comparators
are required to validate the clinical utility of ctDNA for monitoring
of high-risk UM patients for early evidence of metastases. A key
consideration for the use of ctDNA for early detection of disease
relapse is the minimum tumour size/burden and ctDNA shedding
by higher tumour turnover. We have shown in cutaneous
melanoma that ctDNA only becomes consistently detectable at
a metabolic tumour burden of >10 total lesion glycolysis units or
metabolic tumour volume of >4 mm3, both values calculated from
18
F-labelled ﬂuorodeoxyglucose PET-CT scans [109]. Nevertheless,
assay sensitivity may be improved through the optimisation of
pre-analytical, analytical and bioinformatic practices [119]. In our
experience, another key component of ctDNA detectability is the
location of disease. For example, in cutaneous melanoma we
found that patients with intracranial metastases harbour no
detectable ctDNA [120]. In contrast, we observed that lesions
arising in the liver were generally readily detectable through
ctDNA, even at small tumour volumes. Given that liver is the initial
metastatic site in almost all UM cases, ctDNA would be expected
to detect metastatic disease in UM with high sensitivity.
Lastly in metastatic UM, studies utilising ultra-deep sequencing
(without unique molecular identiﬁers (UMI) barcoding), detected
ctDNA in approximately 41% and 80% of patients with metastatic
UM [116, 121]. Other studies, used pyrophosphorolysis-activated
polymerisation to detect ctDNA in 82–95% of patients with
metastatic disease [89, 122–124], or ddPCR detecting ctDNA in
55–100% [81, 85, 125]. The level of ctDNA in metastatic UM has
been shown to correlate with tumour volume [89, 122, 124],
miliary hepatic metastases, quantity of CTCs, progression-free
survival, and overall survival [89]. Furthermore, ctDNA has shown
to be a superior marker of survival prediction compared to CTCs
[89] in metastatic UM.
Another promising clinical use of ctDNA in metastatic UM is the
monitoring of patient response during therapy [123, 125, 126].
Currently, the most comprehensive study monitoring ctDNA in UM
patients throughout a therapeutic intervention showed that
baseline ctDNA correlates with lactate dehydrogenase levels and
the sum of the product of bi-dimensional diameters at baseline
[125]. Furthermore, ctDNA rise preceded radiological progression
of disease with a 4–10-week lead time [125]. Although there are
currently no effective treatments for the long-term survival of UM,
as future treatments become available ctDNA could be a vital
clinical marker of treatment failure and enable the early switch of
treatments. In addition, its inclusion in clinical trials could provide
early evidence of response expediting drug development.
There are many important considerations when assessing
ctDNA (Table 2). Firstly, increasing the plasma/serum or several
mutational targets would increase the sensitivity of ctDNA
detection [127]. In general, most studies in UM outside of those
using next-generation sequencing (NGS) panels, such as Park et al.
2021 or Francis et al. 2021, assess only the known driver mutations
using targeted approaches such as ddPCR or bi-PAP rather than
also encompassing other recurrently mutated genes such as BAP1,
SF3B1 or EIF1AX. Another important pre-analytical consideration is
the choice in blood tube. Firstly, plasma is generally regarded as
the preferred medium as research has shown that serum contains
larger DNA fragments, likely due to apoptosis of haematopoietic
cells during clotting; unique ctDNA molecules and variant allele
frequencies are lower in serum; and rarer mutant ctDNA copies are
undetectable in serum when compared to plasma [128]. While
plasma is generally opted for, there are many different tube types
that affect the detection of ctDNA. Historically, EDTA has been the
preferred solution [129], especially over heparin which is known to
inhibit Taq polymerase. Newer developments have incorporated
EDTA and some form of ﬁxative to extend the window in which
plasma is still viable for ctDNA analysis. Previous research has
shown that apoptosis of leucocytes in EDTA tubes is apparent by
24 hours at room temperature and two days at 4 °C [130]. Whereas
British Journal of Cancer

in ﬁxative tubes, such as Streck cfDNA BCTs, even after seven days
at room temperature there is no evidence of gDNA contamination
from lysed leucocytes [130]. Lastly, double-centrifugation, choice
of extraction kit, and elution volumes have a measurable impact
on the detection of ctDNA. The gold standard for ctDNA has
generally been regarded as the Qiagen Circulating Nucleic Acid
Kit, which has been consistently shown to recover the most cellfree DNA [131, 132]. It is apparent that in UM studies have mostly
opted for EDTA blood tubes and Qiagen extraction kits, however,
elution volumes have been variable. There is some evidence to
suggest that increasing elution volumes improves the overall DNA
yield from Qiagen columns [133].
Circulating Micro RNA
Another circulating nucleic acid that could serve as a blood
biomarker is miRNA (Fig. 3a–c). MicroRNAs are a family of small
non-coding RNA that can regulate gene expression posttranscriptionally. Compelling evidence has demonstrated that
dysregulated miRNA expression is an intrinsic feature of human
cancers. The ﬁrst report of miRNA dysregulation in cancer came
from B-cell lymphoma, where the authors found that deletions to
13q14 in B-cell lymphoma caused down-regulation of miRNAs-15
and 16 [134]. These two miRNAs were later found to affect cell
proliferation [135]. Since then, many studies have demonstrated
that the expression of miRNAs is dysregulated in different tumours
[136]. Cancer cells with abnormal miRNA expression evolve the
capability to sustain proliferative signalling, evade growth
suppressors, resist cell death, activate invasion and metastasis,
and induce angiogenesis [136]. Studies in many different cancer
types and stages have shown that cmiRNA might be useful in
either a diagnostic or prognostic capability in breast (miR-21),
colorectal (miR-21), non-small cell lung (miR-21), or prostate (miR375) cancer, and melanoma (miR-221) [137].
Worley et al. found upregulation of miRNA- let-7b, 143, 199a,
199a*, 193b, and 652 in primary UM tissue, which could
discriminate patients with class 2 from class 1 with 100%
sensitivity and speciﬁcity [138]. Recent advances in the genetic
proﬁling of primary UM tumours revealed four distinct prognostic
classiﬁcations [23]. Within these molecular subsets, four main
miRNA expression clusters were found. These miRNA expression
clusters were associated with monosomy 3 and DNA methylation
[23]. As the levels of miRNA expression appear to correlate with
prognostic classes within the primary tumour, plasma/serum
levels of miRNA might also reveal prognostic information. Reports
of cmiRNA found differentially expressed in UM patients described
in Table 3. However, only one study, so far, has reported on the
prognosis value of plasma miRNAs in primary UM, indicating that
elevated plasma levels of miRNA-96b, miR-199a-5p and miR-233
were detected in patients with monosomy 3 [139].
A study by Stark et al. [140], indicated that miR-211 levels were
signiﬁcantly elevated in serum of metastatic UM patients. In
contrast, a previous study reported that plasma miR-146a,
together with miR-20a, 125b, 155 and 223 were elevated when
metastasis manifested [141]. Further studies are needed to
validate these ﬁndings, as serum/plasma miRNA analysis may
provide a simple strategy for monitoring recurrence in UM
patients.
Although ophthalmologists can generally classify pigmented
choroidal lesions into a naevi or a UM through various imaging
modalities, some pathologies are difﬁcult to differentiate and,
hence, remain classiﬁed as indeterminate choroidal melanocytic
lesions. In addition, the high prevalence of choroidal naevi (~5% of
adults) poses a clinical burden, despite the low risk of
transformation (<1%), with patients requiring yearly monitoring
[142]. Multiple studies have described the potential of plasma/
serum miRNA as a discriminator between healthy controls and
patients with primary or metastatic disease. Differential expression
of circulating miR-20a, 125b, 146a, 155, 181a, and 223 has been

11

RT-PCR

Discovery:
miRNA
microarray
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previously detected in patients with primary disease compared to
healthy controls [141]. In addition, two independent studies have
also identiﬁed upregulation of miRNA-146a in the serum of
patients with UM relative to healthy controls [143, 144]. Recently,
we reported that serum miR-146a, as well as miR-16, miR-145, miR204, miR-211 and miR-363-3p, could differentiate patients with a
benign uveal naevus from patient with primary UM with 93%
sensitivity and 100% sensitivity [140]. However, the number of
participants was low and requires further validation. In general,
blood-based analysis of cmiRNA in UM is lacking and to date, the
only miRNA consistently reported to increase with the development and progression of UM is miR-146a.
There are a few considerations for their analysis and interpretation of cmiRNA (Table 3), and currently one of the largest
challenges in the ﬁeld is their reproducibility. Similar to ctDNA, the
choice of bio-ﬂuid can impact the interpretation of results. Most
cmiRNA studies have utilised serum, and serum may cause miRNA
to be released from blood cells during the coagulation process
[145]. Whereas platelet contamination may be an issue in plasma
samples but can be removed via further centrifugation steps [146].
Therefore, it is important to keep in mind sample type when
comparing across sample types. Again similarly to ctDNA as
described above, the choice of extraction kit is important and
again Qiagen miRNA mini kits appear to the most promising
option currently for consistency and yield [147]. Many studies
have utilised large scale miRNA microarrays for discovery, and
previous research has shown that while intra-platform repeatability is high, inter-platform concordance is poor [148], and it
appears that small RNA-seq is arguably the best overall method
[149] but has not been utilised in UM to date. Lastly, data
normalisation has been an area of debate whether to use the
global mean expression or synthetic spike in controls such as c.
elegans cel-miR-39, and results been methods should be carefully
compared.
Studies assessing cmiRNA in UM currently lack method
standardisation, even more so than those in CTCs and ctDNA.
The results are difﬁcult to compare and the reproducibility of
individual cmiRNA seem unclear. Future studies validating current
ﬁndings are needed to fully elucidate cmiRNA’s ability to provide
diagnostic or prognostic information. Overall there is a lack of
substantive evidence on the clinical validity of cmiRNA as a
biomarker for UM. However, the existing reports suggest that
some cmiRNAs may serve as an indicator of early malignant
transformation of ocular naevi into primary UM.
Exosomes
Both serum and plasma contain small extracellular vesicles known
to contain DNA, RNA, miRNA and proteins [150]. To our knowledge, only three published papers and one published abstract
investigate exosomes as a primary focus in more than 1–2 patients
in UM from the blood. For example, in Ragusa et al. 2015
comparison of serum cmiRNA to vitreous humour and vitreous
humour exosomes in primary UM and revealed that of 27
differentially expressed exosomes in the vitreous exosomes, 6
miRNAs matched both the vitreous humour and vitreous humour
exosomes. Of these, miR-146a appeared to be the most elevated
among the three sample types [143]. Eldh et al. isolated exosomes
from liver perfusate of metastatic UM patients undergoing
isolated hepatic perfusion [151]. The authors found upregulation
of several miRNAs of which only miR-125b and 25 have been
previously reported as differentially expressed in metastatic or
poor prognosis UMs [139, 141]. Next, Frenkel et al. found that the
mean size of exosomes were larger in those that developed
metastases over those who were on observation [152]. Lastly,
Wróblewska et al., 2021 using the Bio-Plex 37-plex human
inﬂammation immunoassay assessed the protein proﬁle of serum
exosomes in primary and metastatic UM. The authors found that
metastatic UM had signiﬁcant enrichment of inﬂammatory
British Journal of Cancer

markers, such as interferon γ, when compared to primary UM,
and thus may potentially be suitable for detecting metastatic UM
[153]. Other studies have combined uveal or ocular melanoma
[154, 155], thus no strong conclusions about UM can be drawn.
However, it does appear that potentially capturing UM exosomes
via MCSP immunomagnetic beads may be more informative [155]
rather than overall proﬁling. Currently, due to the lack of studies,
there is little evidence of the clinical utility of exosomes in UM and
future studies are needed to investigate them more thoroughly as
markers.
FUTURE DIRECTIONS AND CONCLUSIONS
Over the last few decades, we have gained a better understanding
of the biology of UM. However, signiﬁcant improvements in the
clinical outcome of this disease are still lagging. Like with all
cancers, early detection and early treatment could greatly improve
survival outcomes. In this regard, minimally invasive blood tests
have a great potential to improve early diagnosis of primary UM,
disease prognostication and detection of metastatic lesions,
enabling timely and less radical therapeutic interventions (Fig. 4).
Based on our current knowledge, different types of liquid
biopsies can serve different purposes. For example, serum miRNA
may be useful for the identiﬁcation and differentiation of benign
melanocytic lesions from primary UM. This approach would help
alleviate patient’s concerns after diagnosis, and more importantly,
it would allow for earlier interventions, if UM is the conﬁrmed
condition. Treatment of small UM lesions has several advantages,
such as allowing for sight preserving therapy and reducing the risk
of metastases [5].
Following diagnosis of UM, CTCs could be used as a minimally
invasive prognostic test to establish the risk of metastasis.
Currently, the use of tumour biopsies for prognosis purposes
varies signiﬁcantly between practices around the world, generally
affected by fears of poor sight altering outcomes. Using a
minimally invasive prognostic test, such as CTCs, would improve
clinical outcomes by allowing more efﬁcient monitoring of highrisk UM patients, potentially enabling earlier surgical or therapeutic interventions. Furthermore, CTC testing could serve as a
marker to select patients for adjuvant clinical trials. Currently,
various targeted therapies and immunotherapies for UM are
undergoing clinical trials (http://www.clinicaltrials.gov). While
these trials herald a new and promising era with more effective
treatments, it remains crucial to improve the early identiﬁcation of
high-risk patients.
Lastly, ctDNA testing could serve as regular monitoring
modality for the early detection of metastatic disease. This test
could be performed routinely, to function as a complementary test
or as an alternative to expensive and invasive radiological scans.
Earlier detection of metastases will enable more timely treatments
or surgical interventions, both critical to improve patients’
outcomes.
CtDNA could also serve as a suitable method of minimally
invasive treatment monitoring for metastatic UM and could be
used to inform clinicians of changes to tumour burden and,
potentially, early evaluation of response in future clinical trials. In
particular, ctDNA sequencing may help to identify a proportion of
patients likely to respond to immune checkpoint blockade. For
example, although UM carries low number of mutations, iris
melanomas have been shown to carry high tumour mutational
burden which may be predictive of response to immunotherapies
[43]. In addition, evidence suggests that patients with MBD4
mutations respond to immune checkpoint blockade [126], likely
due to the increased tumour mutational burden produced by the
defect which causes wide-scale deamination of 5-methylcytosine
(CpG to TpG).
In the future, liquid biopsies may be able to answer even more
complex questions regarding UM progression. For example, recent

13

A.B. Beasley et al.

14
Suspicious naevi

Primary disease

Metastatic disease

Advanced metastatic disease

CTCs
prognosis

ctdNA
early detection

ctDNA
treatment monitoring

Liquid biopsy

Clinical use

miRNA
diagnosis

Spin: 0
Tilt:-90

Spin: 0
Tilt:-90

Spin: 0
Tilt:-90

Clinical
manifestation
F

Treatment

Fundus photograph of an
indeterminate melanocytic lesion

Fundus photograph of a
choroidal melanoma

N/A

Enucleation / radiation

PET scan of an
isolated liver metastases

1st Line Tx
(e.g., surgery)

F

F
PET scan of
multiple liver metastases

2nd Line Tx
(e.g., immunotherapy)

Fig. 4 Suggested applications of liquid biopsy for the management of uveal melanoma. Plasma cmiRNA proﬁling could be used to
distinguish a suspicious naevus from a small UM lesion. Upon diagnosis of UM, analysis of CTCs can provide information on prognostically
relevant SCNAs. After treatment of the primary tumour, regular monitoring of plasma ctDNA could serve as an early indicator metastatic
disease. Plasma ctDNA can be also used for monitoring of response to treatment and disease progression in patients with metastatic disease.

studies have started to unravel the complexities of the tumour
microenvironment, at a single-cell level, in primary and metastatic
UM. This may one day lead to the discovery of new targets for
therapy [156]. Such studies are possible thanks to novel single-cell
RNA sequencing technologies, which could also help with the
proﬁling of CTCs, to evaluate transcriptional changes that enable
their dissemination throughout the body and the successful
metastatic colonisation of the liver. On the other hand, ctDNA
could be used to monitor genetic and epigenetic changes [157]
during UM tumour development as they adapt and become
resistant to treatment, as has been shown for other cancers.
Altogether, the current evidence strongly suggests that liquid
biopsies are a promising tool in UM to obtain detailed and
valuable tumour information that can improve disease management through a personalised treatment selection, but these
markers still require further investigation due to the lack of
standardisation of methodologies and pre-analytical factors. Due
to the rarity of the disease, large-scale multi-centre trials are
needed to fully validate liquid biopsies in UM.
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